5-6 February 2021 Virtual Conference
|Surgery versus Sorafenib in case of BCLC-C hepatocellular carcinoma: an Italian weighted study
|Current Trends of Hepatocellular Carcinoma Characteristics in Greece
|Patterns of response to atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) from the Phase 1b GO30140 study
|Association between serum magnesium concentration and hepatocellular carcinoma in cirrhotic patients
|The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database
|Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
|Mikel Ruiz de Gauna
|Study on Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy
|Hepatocellular carcinoma prognostic scores: filling the gap?
|A real-world evaluation of baseline characteristics, treatment patterns, and survival outcomes in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein levels receiving second-line therapy in the United States
|Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target?
|Comparison of Sorafenib and Lenvatinib as first line therapy in Unresectable Hepatocarcinoma: a multi-center propensity score matching analysis
|chronic hepatitis b under tenofovir or entecavir: performance of the page-b score to predict hepatocellular carcinoma
|Diagnosing hepatocellular carcinoma are we getting it right first time?
|Modeling hepatocellular carcinoma cells dynamics by serological and imaging biomarkers in patients with response to sorafenib and/or regorafenib
|Profiling of cell-free DNA using Whole-exome sequencing in patients with Hepatocellular carcinoma in Thailand
|Transcriptomic analyses reveal cancer-induce genes in PBMCs of Hepatocellular carcinoma for early diagnosis and prognosis
|Association between postoperative early recurrence of hepatocellular carcinoma and the expression pattern of circulating tumor cells in peripheral blood sample: a preliminary study.
|Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma
|Establishment of 3D-organoids from cryopreserved cancer tissues
|Prognostic role of platelets-to lymphocytes ratio (PLR) and neutrophils-to-lymphocytes ratio (NLR) in hepatocellular carcinoma patients
|Impact of hospital volume on hepatocellular carcinoma survival in Italy
|Sarcomatoid hepatocellular carcinoma has distinct immunologic hallmarks from ordinary hepatocellular carcinoma
|Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study
|Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2cm or smaller: a cohort study in Taiwan
|Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma
|Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma.
|Are undetected stones in the common biliary duct one of the causes of abscesses and bilomas development after percutaneous thermal ablation procedures?
|Different modalities in management of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients with or without hepatocellular Carcinoma
|Copper chelators old drugs for new uses in the treatment of hepatocellular carcinoma
|Silvano Junior Santini
|Diagnostic accuracy of a-fetoprotein (AFP), protein induced by vitamin K absence (PIVKA-II) and fibrogen like protein-2 (FGL-2) for HCC diagnosis among patients with liver cirrhosis
|NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice
|MACARENA HERRANZ ITÚRBIDE
|Development of ex vivo and in vivo tissue models of hepatocellular carcinoma and utility for immunotherapy investigations
|Methylated Septin 9 (mSEPT9) as a biomarker for hepatocellular carcinoma. Results from University Hospital Coventry and Warwickshire NHS Trust, UK
|Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
|PNPLA3 and Notch3 gene polymorphisms as risk factors for alcoholic cirrhosis development and its progression to hepatocellular carcinoma
|Urinary volatile organic compounds characterization in hepatocellular carcinoma pilot study
|Comparison of incidence and mortality risks due to acute kidney injury in hepatocellular carcinoma patients after liver resection, ablation, and transarterial chemoembolization: Meta-analysis of cohort studies
|Boby Pratama Putra
|Predictive value of biomarkers a-fetoprotein (AFP) and fibrogen like protein-2 (FGL-2) for HCC among patients with liver cirrhosis
|Transarterial chemoembolization: Predictors of liver function deterioration prior to hepatocellular carcinoma refractoriness
|Two birds one stone: a case of synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
|Virtual biopsy for diagnosis of steatohepatitis and chemotherapy-associated liver injuries. A combined radiomic and clinical model.
|Hepatic and extrahepatic colorectal metastases have discordant responses to systemic therapy. Pathology data from patients undergoing simultaneous resection of multiple tumor sites
|A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
|Hsa-miR-21-5p disturbs the liver metabolic network in patients with NAFLD and is increased in NASH-associated HCC, contributing to hepatocarcinogenesis in mice
|Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC. A single center retrospective case control study.
|Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash-out
|Chronic disruption of the late cholesterol synthesis leads to female-prevalent liver cancer
|Human antigen R (HuR) SUMOylation is a fine-tuner of hepatocellular carcinoma (HCC) progression via the modulation of key mitochondrial mRNAs
|GALAD Score shows improved detection of early stage hepatocellular carcinoma in a Caucasian cohort of chronic Hepatitis B and C
|Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study.
|Treatment of the chemotherapy induced hepatotoxicity
|Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases
|André L. Simão
|Hepatocellular Carcinoma Surveillance in Cirrhotic patients.
|Dynamic risk profile of hepatocellular carcinoma recurrence after curative intent liver resection
|Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma
|Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients
|Circular RNA expression is modulated by RNA-binding proteins in hepatocellular carcinoma
|The impact of ultrasonographic blind spots for detecting early-stage hepatocellular carcinoma during surveillance
|HA IL KIM
|Prognostic factors and post-treatment survival in patients enrolled onto second-line trials for unresectable hepatocellular carcinoma after sorafenib: a multicentre Italian cohort study
|FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling
|Phase 1 study of autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, LioCyx-M in unresectable HBV-related hepatocellular carcinoma (HCC)
|The combination of alcohol and metabolic syndrome is a fast track to hepatic tumorigenesis
|Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study
|Linda Skibsted Kornerup
|Usefulness of circulating tumor cells in the management of patients with hepatocellular carcinoma
|Elena Vargas Accarino
|Prognostic value of metabolic imaging data of C-choline PET/CT in patients undergoing hepatectomy for hepatocellular carcinoma
|First real-life experience with atezolizumab plus bevacizumab in the treatment of advanced hepatocellular carcinoma
|Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells
|Alteration of miRNA content in extracellular vesicles in Sorafenib-treated liver cancer cells. miRNA prognostic value in plasma from patients with advanced HCC treated with Sorafenib
|Patricia de la Cruz-Ojeda
|Virological and oncological factors of HCC recurrence after liver trasplantation in a single transplant center
|Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma
|Tumor Burden Score: a novel tool to predict immune-related liver injury during immunotherapy for hepatocellular carcinoma
|Phase 3 KEYNOTE-937 Trial: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response After Surgical Resection or Local Ablation
|PRPF8 regulates FAK/AKT pathway via fibronectin 1 splicing modulation to promote hepatocellular carcinoma aggressiveness
|Juan Luis López-Cánovas
|Retrospective analysis of one-center experience in diagnosis and treatment of liver cancer
|Analysis of risk factors associated with hepatocellular carcinoma development in patients with hepatitis B virus infection
|Validation of the aMAP risk score for the development of hepatocellular cancer in patients with cirrhosis in Glasgow
|In vivo quantification of micro-balloon interventions (MBI) advantage. Cohort, retrospective, bi-centric study of DEB-TACE vs b-TACE and SIRT vs b-SIRT
|Comparison of Liver Transplant Criteria for Hepatocellular Carcinoma
|LDH as early prognostic markers for response in advanced hepatocellular carcinoma treated with Nivolumab
|DNA Methyltransferases as Potential Biomarkers for Egyptian Patients with HCV Related Hepatocellular Carcinoma
|Survival analysis of the most frequent Single Nucleotide Variants in Hepatocellular Carcinoma
|Jimmy A. Daza Barragan
|Se and Zn supplements attenuates HCC among recovered Hepatitis C Obese population in Middle Belt Nigeria.
|CAMD score predicts the risk of hepatocellular carcinoma in Tunisian patients with chronic hepatitis B on antiviral therapy
|Centrality of Estrogen Receptor 1 in Modulating Hepatocellular Carcinoma Progression through Wnt signaling
|Hepatoprotective effects of pirfenidone in early stages of hepatocellular carcinoma
|Real-world experience of hepatocellular carcinoma patients after sorafenib treatment: eligibility to subsequent lines and prognostic factors.
|Leonardo Gomes da Fonseca
|Hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors
|Identification of a prognostic 3-protein score of childhood liver cancer by proteomic profiling
|Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome.
|Title: Quantification of extracellular matrix features and its implications in hepatocellular carcinoma patients after curative liver resection
|Enhanced mitochondrial activity and immunometabolic reprogramming, by silencing Methylation Controlled J protein (MCJ), accelerates liver tumorigenesis in a hepatocellular carcinoma (HCC) mice model
|Absence of a complete response after two trans-arterial chemo-embolizations during liver transplantation waiting list: should we persist or change?
|Prediction of early recurrence of hepatocellular carcinoma after resection: international validation of the ERASL risk models
|Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment
|PD-1 expression, polymorphisms in PDCD1 and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD).
|Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma?
|Circulating miR 373 but not miR 210 as a new promising preoperative predictor of response to superive transarterial chemoembolization bridging therapy in Egyptian patients with hepatocellular carcinoma on top of hepatitis C virus infection
|Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients
|Endothelial Angiopoietin-2 overexpression in explanted HCCs identifies subjects at high risk of recurrence after liver transplant
|Role of LI-RADS indeterminate observations in the prediction of HCC occurrence after direct antiviral therapy for hepatitis C virus infection.
|lncRNA-H19 as a marker of liver disease progression: Hepatocellular Carcinoma
|Nanobody-targeted liposomes for photodynamic therapy of Cholangiocarcinoma
|Effectiveness of hepatocellular carcinoma treatments with curative intent: a nationwide study
|Epidemiological trends of hepatocellular carcinoma in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD) in Italy.
|An unexpected side effect of lenvatinib in patients treated for advanced hepatocellular carcinoma: increased hemoglobin level and erythrocytosis
|Are Radiology-based endpoints robust surrogate outcomes of overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization?
|Vimentin expression in hepatocellular carcinoma relates with progenitor cells and epithelial-mesenchymal transition carcinogenesis
|Joana Espírito Santo
|Inducing tissue-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma
|Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment
|A CIRCULATING microRNAs SIGNATURE IDENTIFIES DAA-TREATED HCV-RELATED CIRRHOSIS PATIENTS AT HIGH RISK TO DEVELOP HCC
|Cancer-associated pathways modulated by O-GlcNAc transferase and Enhancer of Zeste homolog 2 in hepatocellular carcinoma
|Assessment of the impact of COVID-19 pandemic on Liver Cancer Management (CERO-19)
|Modified Page B Score Performance in Predicting HCC Risk in patients with chronic hepatitis B on antiviral therapy.
|Fatma Ben Farhat
|CIRCULATING microRNAs PREDICT HEPATOCELLULAR CARCINOMA IN NUC-SUPPRESSED HBV CIRRHOTIC PATIENTS
|Liver decompensation as late complication in HCC patients with long term response following ive internal radiation therapy.
|Diederick van Doorn
|Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma
|Safety and benefit of the combination of regorafenib and nivolumab in patients with hepatocellular carcinoma (HCC) in progression beyond two lines of oral chemotherapy
|Ben merabet Yasmina
|Incidence of Hepatocellular Carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A Systematic Review Meta-Analysis and Meta-Regression
|Marco Sanduzzi Zamparelli
|Performance of ten non-invasive liver function tests in predicting one-year mortality in patients with hepatocellular carcinoma
|Impact of Hepatocellular Carcinoma screening in patients with Non-Achoholic Fatty Liver Disease and survival analyzis: a Brazilian Cross-Section Study
|Regiane Saraiva de Souza Melo Alencar
|Whole-transcriptome profiling of biopsies from unresectable intrahepatic cholangiocarcinoma (iCCA) reveals a prognostic signature with treatment implications.
|Complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or waiting and see strategy?
|PSMA PET/CT imaging has equivalent performance to MRI for characterising hepatocellular carcinoma
|Stellate cell activation in liver cancer treatment
|Efficacy and safety of pemigatinib in European patients with previously treated locally advanced or metastatic cholangiocarcinoma: a FIGHT-202 subgroup analysis
5-6 February 2021 Virtual Conference